HCC Clinical Trial
Official title:
An Open-Label, Non-Randomized, Multi-center Phase 2 Study of YH001 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) and Hepatocellular Carcinoma (HCC)
This is an Open-label, Non-Randomized, Multi-center Phase 2 study of YH001 in Combination with Toripalimab，The study is designed to determine the safety ，tolerability and antitumor activity of YH001 in combination with Toripalimab in subjects with advanced NSCLC and HCC.
This study will include two cohorts of up to 40 subjects each treated with RP2D dose YH001 in combination with 240 mg Toripalimab to assess the antitumor activity and safety/tolerability. According to Simon's two stage design, in the first stage, 9-10 subjects will be accrued. If there are ≤ 1 subjects achieving an objective response, the futility stop will be called. Enrollment will start for the second stage after Stage 1 data pass futility test. In the second stage, 17-19subjects will be enrolled to have 27 subjects in total. If there are ≥ 5 subjects achieving an objective response, a stop could be called for meeting the primary objective. In all cohorts, 4 mg/kg or other higher dose level of YH001 (not exceeding MTD) may be needed based on the safety data in the first stage. - Cohort A: YH001 in combination with Toripalimab in subjects with advanced PD-L1 positive NSCLC as 1st line treatment; - Cohort B: YH001 in combination with Toripalimab in subjects with previously systemically treated advanced HCC as 2nd line treatment; ;
| NCT number | NCT05212922 |
| Study type | Interventional |
| Source | Eucure (Beijing) Biopharma Co., Ltd |
| Contact | Ryan Wen |
| Phone | +86 01085950770 |
| [email protected] | |
| Status | Not yet recruiting |
| Phase | Phase 2 |
| Start date | March 2022 |
| Completion date | June 2023 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05022628 -
Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis
|
Phase 4 | |
| Enrolling by invitation |
NCT02256514 -
Open Label Trial of Immunotherapy for Advanced Liver Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04542837 -
The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT05025592 -
cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
|
||
| Terminated |
NCT02785874 -
Statin With Palliative Therapy for HCC
|
N/A | |
| Not yet recruiting |
NCT02715492 -
Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.
|
Phase 3 | |
| Completed |
NCT02985034 -
Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT
|
N/A | |
| Suspended |
NCT02935478 -
Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation
|
N/A | |
| Completed |
NCT03176485 -
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
|
N/A | |
| Completed |
NCT02675920 -
A Study of HCC High Risk Group Using Two Surveillance Tools
|
||
| Completed |
NCT02833298 -
Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening
|
N/A | |
| Recruiting |
NCT04588051 -
Cabozantinib in Hepatocellular Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT03314532 -
The Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma
|
N/A | |
| Recruiting |
NCT03097848 -
Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma
|
N/A | |
| Completed |
NCT03045445 -
"Double Low-Dose" DECT for HCC Imaging
|
N/A | |
| Active, not recruiting |
NCT03893695 -
Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01356628 -
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT02415283 -
OBT Measurement to Differentiate Between Presence and Absence of HCC Determined by MRI
|
Phase 2 | |
| Recruiting |
NCT04611373 -
Clinical Study on the Efficacy of Acetazolamide Combined With Levamisole in the Treatment of HCC
|
Phase 3 | |
| Recruiting |
NCT03104920 -
ERAS Program Improves Recovery of HCC Patient Undergoing Hepatectomy
|
N/A |